VTE Prevention Following Total Hip and Knee Arthroplasty
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Venous Thromboembolism
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: randomized, controlled, double-blindMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: over-encapsulated rivaroxaban/ASAPrimary Purpose: Prevention
Participation Requirements
- Age
- Between 16 years and 125 years
- Gender
- Both males and females
Description
Aspirin and rivaroxaban prevent venous thromboembolism (VTE) via different mechanisms. Aspirin is significantly cheaper than rivaroxaban. Aspirin in combination with rivaroxaban was shown to be safe and efficacious in a non-inferiority trial (EPCATII) when compared to rivaroxaban alone. This study w...
Aspirin and rivaroxaban prevent venous thromboembolism (VTE) via different mechanisms. Aspirin is significantly cheaper than rivaroxaban. Aspirin in combination with rivaroxaban was shown to be safe and efficacious in a non-inferiority trial (EPCATII) when compared to rivaroxaban alone. This study will assess if aspirin alone is non-inferior to rivaroxaban and aspirin in the prevention of venous thromboembolism.
Tracking Information
- NCT #
- NCT04075240
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Nova Scotia Health Authority
- Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
- Investigators
- Principal Investigator: Sudeep P Shivakumar, MD Dalhousie University/Nova Scotia Health Authority
Get Well Soon